Expression of CLN3 Gene in Ovarian Serous Cancer

[Purpose] To explore the relationship between expression of CLN3 gene and its biological behaviors in ovarian serous cancer. [Methods] The expression of CLN3 in 45 cases with ovarian serous tumor (23 cases with ovarian serous cancer, 11 cases with borderline ovarian serous tumor, 11 cases with benign serous tumor) and 12 cases of normal ovarian tissue were detected by reverse-transcription polymerase chain reaction (RT-PCR) and Western blot methods. [Results] The expression of CLN3 mRNA was 3.04±0.58 in ovarian serous cancer and 1.63±0.43 in borderline ovarian serous tumor. The expressions of CLN3 mRNA in ovarian serous cancer and borderline ovarian serous tumor were significantly higher than those in benign ovarian serous tumor and normal ovarian tissue (P0.01). The expression of CLN3 mRNA in ovarian serous cancer was higher than that in borderline ovarian serous tumor (P0.01). There was significantly difference between stageⅠ/Ⅱ and Ⅲ~/Ⅳ, G1/G2 and G3, with and without ascites (P0.05). [Conclusion] CLN3 might be related to the carcinogenesis and prognosis of ovarian serous cancer and become an important biological marker for ovarian serous cancer.